Aspirin Drugs Market Expected to Reach $1.8 Billion by 2035

According to a new report published by Allied Market Research, titled, “Aspirin Drugs Market," The aspirin drugs market size was valued at $1.3 billion in 2023, and is estimated to reach $1.8 billion by 2035, growing at a CAGR of 2.7% from 2024 to 2035.

Aspirin, also known as acetylsalicylic acid (ASA), is a widely used nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and anti-inflammatory properties. It works by inhibiting cyclooxygenase (COX) enzymes, reducing the production of prostaglandins, which are responsible for pain, inflammation, and fever. Aspirin is commonly used to relieve mild to moderate pain, such as headaches, muscle aches, and arthritis. In addition, it plays a crucial role in cardiovascular disease prevention by inhibiting platelet aggregation, reducing the risk of heart attacks and strokes in high-risk patients. Recent studies suggest potential benefits in cancer prevention, particularly colorectal cancer is driving the aspirin drugs market trends. Despite its effectiveness, prolonged use can cause gastrointestinal irritation, ulcers, and bleeding. Available in various formulations, including tablets, enteric-coated forms, and effervescent powders, aspirin remains to be a fundamental treatment in pain management and cardiovascular therapy.

Rise in prevalence of diseases is a significant factor driving the aspirin drugs market growth. Increasing incidence of cardiovascular diseases, arthritis, migraines, and inflammatory conditions has led to a surge in demand for aspirin as a primary or adjunct treatment. Cardiovascular diseases, including heart attacks and strokes, remain a leading cause of mortality, necessitating the widespread use of aspirin as an antiplatelet agent to prevent blood clot formation. In addition, rise in prevalence of chronic pain disorders, such as osteoarthritis and musculoskeletal pain, has increased the need for cost-effective pain management solutions, further boosting aspirin consumption. Also, the presence of generic aspirin formulations is another crucial factor contributing to aspirin drugs market growth. Several pharmaceutical companies manufacture low-cost, generic versions of aspirin, increasing accessibility for a wider population.

Moreover, availability of various dosage of aspirin, ranging from 81 mg to 500 mg, ensures that aspirin can cater to diverse patient needs and treatment regimens. The 81 mg low-dose aspirin is widely used for cardiovascular disease prevention, while higher dosages, such as 325 mg or 500 mg, are prescribed for pain relief and inflammatory conditions. This broad dosage availability allows healthcare providers to tailor treatments based on individual patient requirements. Rise in prevalence of cardiovascular disease, growing need for pain management solution, affordability of generic aspirin, and flexible dosage options continue to fuel the aspirin drugs market opportunity, ensuring aspirin remains a widely used and essential medication across multiple therapeutic applications.

The aspirin drugs industry is segmented into dosage form, application, distribution channel, and region. On the basis of dosage form, it is segmented into tablets, capsules, and others. The tablet segment dominated the market share in 2023, owing to its widespread availability, ease of administration, and precise dosage control. Tablets offer longer self-life, cost-effectiveness, and patient convenience, making them the preferred choice for both prescription and over the counter (OTC) use. In addition, advancements in enteric-coated and extended-release formulations have enhanced patient compliance by reducing gastrointestinal side effects.

However, the others application segment is expected to register the highest CAGR during the aspirin drugs market forecast period owing to its expanding use in specialized treatments. Injectable aspirin is gaining traction in emergency cardiovascular care, while aspirin suppositories are preferred for patients with gastrointestinal issues or difficulty swallowing. In addition, granules offer flexible dosing, enhancing patient compliance and market growth.

On the basis of application, the market is divided into pain relief, cardiovascular disease prevention, anti-inflammatory uses, and other applications. The pain relief segment dominated the aspirin drugs market size in 2023, owing to its widespread use in managing headaches, muscle aches, and other pain-related conditions. Aspirin’s proven efficacy as an analgesic, along with its availability in various formulations, has contributed to its strong demand. Additionally, the increasing prevalence of chronic pain and growing consumer preference for over-the-counter (OTC) pain relievers have further driven the segment's growth.

However, the others segment is expected to register the highest CAGR during the forecast period owing its expanding therapeutic applications. Aspirin’s antipyretic properties continue to drive demand for fever treatment, while its antithrombotic effects are increasingly utilized in post-surgical recovery to prevent clot formation. In addition, ongoing clinical trials investigating aspirin’s potential in esophageal cancer prevention and treatment are fueling research investments, further accelerating the market growth.

On the basis of distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment dominated the aspirin drugs market share in 2023, owing to its widespread accessibility, strong distribution networks, and growing consumer preference for over-the-counter (OTC) medications. Retail pharmacies offer convenient purchasing options, professional guidance from pharmacists, and wide range of aspirin formulations. In addition, increasing self-medication trends, especially for pain relief and cardiovascular disease prevention, along with the expansion of pharmacy chains in emerging markets, contributed to the segment growth in the aspirin drug market.

However, the online pharmacies segment is expected to register the highest CAGR during the forecast period owing to rise in adoption of e-commerce, increase in internet penetration, and convenience of home delivery. Online platforms offer competitive pricing, easy accessibility, and doorstep delivery, making them an attractive option for consumers. In addition, rise of telemedicine services, availability of digital prescriptions, and expanding regulatory approvals for online drug sales are further driving growth in the segment, especially in regions with a strong digital healthcare infrastructure.

Region-wise, North America was the largest shareholder in the aspirin drugs industry in 2023, owing to rise in prevalence of cardiovascular diseases, widespread awareness of preventive healthcare, and strong healthcare infrastructure. The region benefits from substantial healthcare investment, a well-established pharmaceutical industry, and presence of major market players. In addition, increase in geriatric population, rise in adoption of OTC drugs, and favorable regulatory policies have further fueled the demand for aspirin in both prescription and over-the-counter applications.

However, Asia-Pacific is anticipated to register the highest CAGR during the forecast period owing to rise in prevalence of cardiovascular diseases, rise in healthcare awareness, and increase in geriatric population. The region is witnessing rapid urbanization, improved healthcare infrastructure, and expanding pharmaceutical manufacturing capabilities, making aspirin drugs more accessible. In addition, rise in OTC drug adoption, increase in disposable income, and government initiatives to improve cardiovascular health are further driving the market growth in the region. Expansion of online pharmacies also contributes to the growth of the market in the Asia-Pacific region.

Key findings of the study

• On the basis of dosage form, the tablet segment dominated the aspirin drugs market share in 2023. However, the others segment is anticipated to grow at the highest CAGR during the forecast period.
• On the basis of application, the pain relief segment dominated the market share in 2023. However, the others segment is anticipated to grow at the highest CAGR during the forecast period.
• On the basis of distribution channel, the retail pharmacies segment dominated the market share in 2023. However, the online pharmacies segment is anticipated to grow at the highest CAGR during the forecast period.
• Region-wise, North America generated the largest revenue in 2023. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.